Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Clinical trial NCT02598388 · COMPLETED

Trial details

NCT number: NCT02598388
Sponsor: Janssen Vaccines & Prevention B.V.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hemorrhagic Fever, Ebola

Start date: 2015-12-10
Primary completion: 2018-12-12
Enrollment: 578

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.